Hemispherx Biopharma and Max Neeman International Team Initiate Influenza Research Programs

Thursday, April 1, 2010 General News
Email Print This Page Comment
Font : A-A+

. . . Clinical Sites Targeted to Enroll Subjects Beginning in Upcoming Monsoon Season

Company/Investor Contact:

Company/Investor Contact:

Dianne Will

Donald Swankie

Hemispherx Biopharma, Inc.

Max Neeman International

518.398.6222

919.424.3345

ir@hemispherx.net

donald.swankie@neeman-medical.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook